Teva Announces Positive Phase 2a Results for Anti-IL-15 Antibody in Celiac Disease
Product·2 articles across 2 outlets·◆ Primary source
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Teva Pharmaceutical has reported positive topline results from its Phase 2a study of an anti-IL-15 antibody for celiac disease. This outcome is seen as a validation of Teva's pipeline and its potential to develop a first-in-class autoimmune therapy.
The study's success keeps Teva's aspirations for a significant breakthrough in autoimmune treatments alive, as the company aims to position its therapy as a leading option in the market for celiac disease.
Teva
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-i…”
SEC Filing — Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-i…
AnalysisInterprets it
SupportCorroborates it
“Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac disease.”
fierce biotech — <a href="/biotech/teva-autoimmune-antibody-notches-ph-2-win-celiac-disease" hreflang="en">Teva autoimmune antibody notches ph. 2 win in celiac disease</a>